The NEJM study, although specific for blood disorders, could be extrapolated to other tumor types as well, to develop personalized treatment regimens, the authors suggest.
For the first time, researchers have proved that the order in which cancer genes mutate affects the type of malignancy that results and its response to treatment. Although the findings are specific to a particular group of preleukemic disorders known as myeloproliferative neoplasms, they suggest that scientists studying other types of tumors should start taking into account the timing of the underlying genetic mutations as a potentially critical factor in establishing an accurate diagnosis as well as in making choices about treatment. The study, which was conducted by investigators in the U.K., Spain and Germany, was published in the
of
.
Link to the report on Scientific American:
February 11 issueTheNew England Journal of Medicinehttp://bit.ly/1Mgcs71
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen